Literature DB >> 34353566

Editorial Commentary: More Clinical Trials Should Focus on Primary Prevention of Osteoarthritis: Disruptive Thinkers Are Required.

Erik Hohmann.   

Abstract

With increasing life expectancy and an increased prevalence of osteoarthritis, the total number of individuals with symptomatic degenerative arthritis will most likely increase considerably. The current focus of nonoperative treatment is on weight loss, exercise, muscle strengthening, physical therapy, nonsteroidal anti-inflammatory drugs, intra-articular injection therapies with corticosteroids, hyaluronic acid, or platelet-rich plasma, and lately, disease-modifying drugs. Obviously, prevention is better than cure, but only 5% of all studies registered on ClinicalTrials.gov in the United States are intending to develop strategies for prevention. The overall majority of included studies (89%) will target symptom resolution, and 6% will investigate disease-modifying drugs.
Copyright © 2021 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 34353566     DOI: 10.1016/j.arthro.2021.05.009

Source DB:  PubMed          Journal:  Arthroscopy        ISSN: 0749-8063            Impact factor:   4.772


  1 in total

1.  Projected number of osteoarthritis patients in Austria for the next decades - quantifying the necessity of treatment and prevention strategies in Europe.

Authors:  Wolfgang Hitzl; Tanja Stamm; Margreet Kloppenburg; Markus Ritter; Martin Gaisberger; Antje van der Zee-Neuen
Journal:  BMC Musculoskelet Disord       Date:  2022-02-09       Impact factor: 2.362

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.